Company intelligence / Profile preview

Celonic

Basel, Basel-City, Switzerlandcelonic.com ↗

Ownership: Private
Employees: ~302
Development stage: Other

Overview

Celonic does not have its own clinical pipeline but provides end-to-end development and GMP manufacturing services for biologics—including cell line development, process optimization/scale-up/tech transfer—for biotech/pharma clients. It has integrated next-generation technologies like the Breez™ micro-bioreactor to enhance efficiency in monoclonal antibody production. No direct clinical results are reported since it operates as a CDMO rather than a product company.

Modalities: Monoclonal antibodyBispecific monoclonal antibodyRecombinant proteinBiologic
Industry: Contract Manufacturing Organization

Partnerships

Merck KGaA

Beyond the preview

Go deeper on Celonic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celonic.

Explore the full profile